Background. Although it effectively suppresses parathyroid hormone (PTH) secretion, vitamin D [1,25(OH) 2 D 3 ] therapy often causes tissue calcification over the long term. In patients on chronic dialysis, cardiovascular calcification is clearly linked to an unfavourable prognosis. In pre-dialysis patients, renal calcification of the kidney leads to the deterioration of renal function. Methods. We compared the propensities of 22-oxacalcitriol (OCT), with lesser calcaemic action, and 1,25(OH) 2 D 3 for producing their potential side effects in rats: (i) metastatic calcification of heart and aorta, and (ii) renal dysfunction with nephrocalcinosis, using the same effective doses for hyperparathyroidism. OCT (1.25 and 6.25 mg/kg) or 1,25(OH) 2 D 3 (0.125 and 0.625 mg/kg) solutions were administered intravenously to subtotally nephrectomized (SNX) rats three times weekly for 2 weeks. Results. Despite the suppression of PTH to comparable levels, the calcification of the hearts, aortas and kidneys in the 1,25(OH) 2 D 3 -treated group was significantly greater than in the OCT-treated group. Of interest was that, in the OCT (6.25 mg/kg) group, the degree of calcification in hearts, aortas and kidneys were distinctly lower than those in the 1,25(OH) 2 D 3 (0.125 mg/kg) group despite the comparable serum Ca Â Pi products. Therefore, there may be different mechanisms behind the calcifications resulting from OCT and 1,25(OH) 2 D 3 . Deterioration of renal function, tubular changes, and atypical hyperplasia of proximal tubules associated with calcification were more severe in the 1,25(OH) 2 D 3 -treated group than in the OCT-treated group. Conclusions. These results indicate that OCT may be an effective agent for the suppression of PTH with a lesser risk of cardiovascular calcification or deterioration of residual renal function.
Introduction
Vitamin D [1, 25(OH) 2 D 3 ] pulse therapy has been routinely used to treat secondary hyperparathyroidism (2HPT) [1] . Despite its effectiveness, this long-term therapy often causes metastatic calcification in several tissues, such as the heart, lung, aorta and kidney, because of hypercalcaemia [2] . Cardiovascular events represent the leading cause of death in dialysis patients, accounting for nearly half of all deaths among patients with end-stage renal disease (ESRD) [3, 4] . These patients frequently have hyperphosphataemia as well as an excess calcium load, which elevate the Ca Â P product, thereby contributing to the development of calcific complications [5] . Mismanagement of calcium and phosphorus metabolism during the treatment of 2HPT has been implicated as a major factor in the development of soft tissue calcification and cardiovascular disease. Nephrocalcinosis, which contributes to tubular damage and interstitial fibrosis, also causes renal dysfunction [6, 7] . Thus, long-term 1,25(OH) 2 D 3 therapy carries a high risk of accelerating cardiovascular disease and renal dysfunction associated with calcification.
In preclinical studies, 22-oxacalcitriol (OCT), a unique 1,25(OH) 2 D 3 analogue, has been shown to have less calcaemic [8] and less antiphosphaturic effects [9] than 1,25(OH) 2 D 3 . This treatment prevents 2HPT and renal osteodystrophy without causing hypercalcaemia and hyperphosphataemia in rats [10] and dogs [11] . Therefore, we believe that OCT has an advantage over 1,25(OH) 2 D 3 due to the lower risk of side effects.
In this study, we compared OCT and 1,25(OH) 2 D 3 with respect to their risk of producing the following side effects: (i) metastatic calcification of heart and aorta, and (ii) renal dysfunction associated with nephrocalcinosis, using the same effective dose for 2HPT in subtotally nephrectomized (SNX) rats.
Materials and methods

Experimental protocol
Male, 7-week-old Sprague-Dawley rats were used as subjects. The nephrectomy was performed with a standard two-step operation. Briefly, after an acclimation period of 1 week, rats were anaesthetized with diethyl ether and two-thirds of their left kidneys were surgically removed. One week later, a right nephrectomy was performed. In sham-operated rats, both kidneys were only decapsulated. All rats were then maintained in sterilized cages and fed standard rodent chow containing 1.18% calcium and 1.03% phosphate (CE-2, Clea Japan Inc.). Food and water were provided ad libitum. At 10 weeks after the second step of nephrectomy, the rats were divided into five groups with comparable serum creatinines (Cr) and body weights (BWs). The treatment groups were as follows: Group 1, sham-operated vehicle-treated control group (sham-control group: n ¼ 6); Group 2, SNX vehicletreated control (SNX-control group: n ¼ 9); Group 3, SNX-OCT 1.25 mg/kg BW (low-dose OCT-treated group: n ¼ 8); Group 4, SNX-OCT 6.25 mg/kg BW (high-dose OCT-treated group: n ¼ 8); Group 5, SNX-1,25(OH) 2 D 3 0.125 mg/kg BW (low-dose 1,25(OH) 2 D 3 -treated group: n ¼ 8); Group 6, SNX-1,25(OH) 2 D 3 0.625 mg/kg BW (high-dose 1,25(OH) 2 D 3 -treated group: n ¼ 8) as a positive control of calcification. The OCT used was synthesized at Chugai Pharmaceutical Co., Ltd. (Gotemba, Japan). The 1,25(OH) 2 D 3 was purchased from Solvay Dupher (USA). These compounds were dissolved in phosphate-buffered saline (pH 8.0) containing 0.2% ethanol and 0.01% Tween 20. The OCT and 1,25(OH) 2 D 3 solution or vehicle (volume 100 ml/100 g BW) were administered intravenously three times per week for 2 weeks, via tail veins without anaesthesia. The amount of vehicle was 1 ml/kg BW. After the final administration, rats were put in metabolic cages, and urine samples were collected. After that, the rats were killed under diethylether anaesthesia, and blood samples were obtained from their abdominal aortas; after death, aortas, hearts and kidney remnants were removed and stored at -20 C until measurements of tissue calcium and phosphorus were carried out. This study was performed in compliance with Chugai Pharmaceutical's ethical guidelines for animal care and the animal care committee of our institution approved the research protocols.
Measurements of biochemical parameters
Serum calcium (Ca), serum phosphorus (Pi), Cr, urinary calcium (uCa), urinary phosphorus (uPi) and urinary Cr were measured using an autoanalyser (Hitachi 7170; Hitachi, Tokyo, Japan). Serum N-PTH was measured using a rat parathyroid hormone (PTH) (IRMA) kit (Immutopics, Inc., San Clemente, USA).
Tissue preparation
The kidneys were dissected in a plane perpendicular to their interpolar axes and divided into three parts, of which two were fixed in 20% neutral-buffered formalin, and embedded in paraffin. The other was frozen at -20 C until Ca and Pi could be measured. One of the paraffin sections was stained by the von Kossa method and then counterstained with haematoxylin. The other was stained with HE stain. The aortas and hearts were removed and Ca and Pi concentrations in a part of each of them were determined. Their remnants were stained by the von Kossa method.
Measurements of Ca and Pi contents in aorta, heart and kidney
We performed the measurements of Ca and Pi contents in aortas, hearts and kidneys as described previously [12] . Briefly, after lyophilization, dried aortas, hearts and kidneys were delipidized with a mixed solution of chloroform and methanol (2:1) for 48 h, and then dehydrated with acetone for 3 h. Samples were incinerated to ash at 900 C for 12 h using an electric muffle furnace (KDF S90; Denken Co., Ltd, Kyoto, Japan), and then were dissolved in hydrochloric acid. These solutions were diluted with adequate volumes of distilled water, and Ca and Pi concentrations were measured using an autoanalyser (Hitachi 7170, Hitachi Co. Ltd, Tokyo, Japan).
Measurement of atypical hyperplasia of epithelial tubules (AHET)
To evaluate the relationship between renal dysfunction and morphological changes, we counted the foci of proliferative epithelial tubules in all areas of sections stained with HE. The foci consisted of bizarre epithelial cells projecting toward the lumen, which were designated as atypical hyperplasia of epithelial tubules (AHET). The histological evaluation and scoring of AHET were performed by two independent pathologists.
Statistical analysis
Statistical analysis was performed with statistical analysis software (SAS, version 6.12). A single ANOVA was used for comparisons between groups. The correlation was tested using Pearson's product moment correlation coefficient. A P-value of <0.05 was considered significant.
Results
Body weight and biochemical parameters
At sacrifice, the BW of SNX-control rats, OCT-treated groups and the 1,25(OH) 2 D 3 -treated group were slightly lower compared with sham-control rats. A significant elevation of serum N-PTH levels was 22-Oxacalcitriol suppresses PTHobserved in SNX-control rats compared with shamcontrol rats (Table 1) . In contrast, both OCT and 1,25(OH) 2 D 3 inhibited the serum N-PTH levels significantly [OCT (1.25 mg/kg), P < 0.05; OCT (6.25 mg/ kg), P < 0.01; 1,25(OH) 2 D 3 (0.125 mg/kg), P < 0.05] ( Table 1) .
To correlate the side effects of these compounds to their suppression of serum N-PTH levels at the same effective dose, we measured the concentrations of Ca and Pi in serum and urine at the end of treatment. Although both OCT and 1,25(OH) 2 D 3 elevated serum Ca significantly, the increase associated with the OCT treatment was weaker compared with the 1,25(OH) 2 D 3 treatment. OCT resulted in no significant dosedependent elevation of Pi levels in serum or urine. Both OCT and 1,25(OH) 2 D 3 elevated the serum Ca Â Pi product significantly ( Table 2 ). In addition, the serum Ca Â Pi product in the 1,25(OH) 2 D 3 group was comparable to that in the high-dose OCT group (Table 2) . OCT and 1,25(OH) 2 D 3 had no effect on creatinine clearance (CCr) ( Table 1) .
Metastatic calcification in heart and aorta Figure 1 shows Ca and Pi concentrations in the heart and aorta at the end of treatment. There was no significant difference between the Ca and Pi concentrations in SNX-control rats and sham-control rats. Comparing the same effective doses for PTH inhibition, OCT treatment also produced levels of Ca and Pi comparable to those in the SNX-control groups, while 1,25(OH) 2 D 3 treatment was associated with a significant elevation of both elements in the heart. Interestingly, despite the comparable effects on the Ca Â Pi products, Ca and Pi concentrations in the tissues of the high-dose OCT group were significantly lower than their concentrations in the low-dose 1,25(OH) 2 D 3 group. Figure 2 shows representative sections of heart, coronary artery and aorta stained by von Kossa staining. Ca deposition in the high-dose 1,25(OH) 2 D 3 group ( Figure 2D ) was observed in the valves (arrow) and muscle (asterisk) of the heart. Severe calcification and slight dilatation were also observed in the coronary arteries and the aortae in this group. On the other hand, there was no calcium deposition in the heart and the aorta in the high-dose OCT group. Figure 3 shows the Ca and Pi content of the kidney at the end of treatment. Both Ca and Pi in the kidneys of SNX-control rats were comparable with those in the sham-control rats. In contrast, Pi deposits in the lowdose 1,25(OH) 2 D 3 group were elevated significantly compared with those in the low-dose OCT group. The deposits were not found even in the high-dose OCT group in spite of a significant elevation of uCa. Figure 4 shows representative sections of a kidney stained by the von Kossa method. Prominent calcification was observed along the basement membranes of tubules in the high-dose 1,25(OH) 2 D 3 group, but not in the high-dose OCT group. Figure 5 shows the effects of OCT and 1,25(OH) 2 D 3 at the end of treatment on a number of AHET foci, which are represented by asterisks ( Figure 6 ). The AHET and calcification (arrow) were observed along the basement membranes of the tubules. The mean AHET score (i.e. mean number of foci) in the SNX-control group was slightly, but not significantly, elevated. Although the low-dose 1,25(OH) 2 D 3 group showed a significant elevation of the AHET score, the OCT group did not. Table 3 shows the correlation between AHET and Ca and Pi concentrations in serum and kidney. A significant correlation with the AHET score was apparent for serum Pi, serum Ca Â Pi, kidney Ca, and Pi content, and for the kidney Ca Â Pi. In contrast, 
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there was no significant correlation between AHET and serum Ca.
Discussion
We have previously demonstrated that 1,25(OH) 2 D 3 was 10 times as potent as OCT in suppressing serum PTH levels in the same setting [13, 14] . In clinical settings, OCT has usually been prescribed at 10 times the dosage of 1,25(OH) 2 D 3 (OCT, 10 mg/patient/ haemodialysis session; 1,25(OH) 2 D 3 , 1 mg/patient/haemodialysis session). Therefore, we used OCT at 10 times the dosage of 1,25(OH) 2 D 3 in this and previous animal studies.
In this study, we demonstrated that using OCT carried a significantly lower risk of inducing metastatic calcification than did the use of 1,25(OH) 2 D 3 when these compounds were used in doses that exerted comparable PTH suppression, and even when serum Ca Â Pi products were similar. Although areas positive to von Kossa staining were not observed in the low dose 1,25(OH) 2 D 3 group, the Ca and Pi concentrations in aorta, heart and kidney were appreciably higher than with OCT treatment. These findings suggest that different mechanisms might be operating in the induction of metastatic calcification by either of these compounds. The possible explanations for this effect are: First, it is well known that, in vitro, 1,25(OH) 2 D 3 has a stimulatory effect on calcification in bovine vascular smooth muscle cells [15] and human aortic smooth muscle cells [16] . In keeping with this calcification process, it was revealed that 1,25(OH) 2 D 3 promoted calcium deposits in cells [16] . Therefore, 1,25(OH) 2 D 3 is considered to be one of the risk factors of vascular calcification. In spite of rapid clearance from blood circulation [17] , OCT reaches the parathyroid gland more quickly than does 1,25(OH) 2 D 3 [18] , thereby inhibiting serum PTH levels without hypercalcaemia. Thus, the concentration of OCT in serum would not reach levels high enough to promote calcification, which might be one factor that contributes to a lower risk of metastatic calcification despite the high Ca Â Pi products. The second explanation is that the direct effects on the vascular calcification, such as through the depression of ALP activity and PTH-related peptides, might be different for these two compounds. This is speculation, but important for the planning of future research.
As for uCa excretion, in this study, there was no significant difference between the OCT (6.25 mg/kg) and 1,25(OH) 2 D 3 (0.125 mg/kg) groups (ANOVA: P < 0.281); the serum Ca Â Pi products were similar. Therefore, in this study, the Ca and Pi loads into tissues between these groups might be similar. It is thought meaningless to evaluate the risk of calcification by only comparing the serum Ca Â Pi products in the model rats that maintain uCa and uPi excretion, with those in dialysis patients. In this study, however, since a condition of our comparison was that there be similar levels of serum and urine Ca and Pi in the groups studied, we believe that our results could be valuable in clinical settings. Therefore, OCT may be preferable in the long-term therapy of 2HPT with less risk of cardiovascular calcification in chronic dialysis patients.
It is known that some pre-dialysis patients have experienced renal osteodystrophy associated with 2HPT. Controlling serum PTH levels would increase the quality of life for these patients after the initiation of dialysis, and therefore, 1,25(OH) 2 D 3 therapy would be valuable in treating them. This therapy, however, has a high risk of producing deterioration of renal function, and could be partly responsible for the nephrocalcinosis in tubules that is due to the hypercalcaemia associated with 1,25(OH) 2 D 3 intake [19] . Nephrocalcinosis, which is observed in the early stages of renal disease in humans, is mainly promoted by HPT. Chronic PTH stimulation results in cellular changes and death, which induces the increase of ionized calcium in the cytosol in proximal tubular cells [8] . Following this, inflammatory and sclerotic reactions to the dead cells contribute to tubular damage, i.e. tubular degeneration and interstitial fibrosis [7] . In addition, it is known that calcium deposits are strongly correlated with the functional impairment of the kidney [7] . In our present study, supra-physiological doses of 1,25(OH) 2 D 3 induced AHET related to nephrocalcinosis, but OCT affected neither AHET nor nephrocalcinosis. The AHET changes associated with calcification are partly similar to the micropolyp formation in medullary collecting tubules caused by high protein diets [20] . CCr in the high-dose 1,25(OH) 2 D 3 group deteriorated with severe calcification in the tubules (data not shown). In addition, significant correlations were observed not only between AHET and the serum Ca Â Pi products but also between it and the renal concentrations of Ca and Pi (Table 3) . Therefore, we believe that it might be valuable in the management of the side effects of 1,25(OH) 2 D 3 on tubular epithelium to assess the changes associated with calcification. Thus, the induction of AHET correlated with tubular calcification resulted in renal deterioration. We believe that the situation in which tubular epithelium shows high turnover due to subtotal nephrectomy to be at least partially paralleled in pre-dialysis patients. In all, OCT carries a lower risk of inducing AHET than does 1,25(OH) 2 D 3 during PTH suppression, which suggests that OCT could be a more useful agent for controlling PTH levels of pre-dialysis patients without causing renal deterioration.
In conclusion, OCT might be a clinically useful and safe agent in the management of 2HPT, due to both its lower calcaemic action and lower propensity to induce metastatic calcification. Further clinical studies are envisioned.
